Trial reportThe Journal of infectious diseases2026
Intracellular Ganciclovir Triphosphate Concentrations in Children With Congenital Cytomegalovirus Infection.
Trial report in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A novel hollow-fiber infection model (HFIM) for antiviral PK/PD studies of CMV infection.Antimicrobial agents and chemotherapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCongenital cytomegalovirus (cCMV) infection is the most common cause of nonhereditary pediatric sensorineural hearing loss (SNHL). Importantly, cCMV is treatable, with the primary option being ganciclovir (GCV) or its orally bioavailable pro-drug valganciclovir (VGCV). A challenge for treating cCMV is the elevated risk for neutropenia associated with standard dosing. Optimizing and individualizing (V)GCV dosing could ameliorate the risk of neutropenia and improve efficacy but requires an understanding of the complex intracellular phosphorylation processes that govern the formation of the active GCV-triphosphate (GCV-TP) moiety. This study utilizes dried blood spot (DBS) samples from infants with cCMV to quantify GCV-TP and explore the kinetics of GCV-TP in this matrix.
methodsDBS samples were collected from infants with cCMV infection receiving 16 mg/kg VGCV twice daily as part of either a randomized, placebo-controlled clinical trial (ValEAR) or an open-label PK study. GCV-TP concentrations in DBS were determined using LC-MS/MS.
resultsData indicate that GCV-TP is long-lived in DBS, with a half-life approximating 21 days. This leads to extensive GCV-TP accumulation in this matrix (primarily consisting of erythrocytes), with an expected approximately 62-fold difference in first-dose and steady-state concentrations. Simulated data highlight the potential for DBS GCV-TP to be used as an objective adherence marker.
conclusionsThese findings underscore the need to define the kinetics of GCV-TP in cell matrices relevant to its activity to determine appropriate VGCV dosing strategies in this population and establish safe and define effective therapeutic concentration targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.